In COVID-19 clinical update #85, Dr. Griffin reviews cases and deaths by vaccination status, mRNA vaccine effectiveness in 12-18 year olds, standard and extended dosing of mRNA vaccines, immune responses after vaccination, Moderna booster dose approved, giving monoclonals at home, no benefit from colchicine, and IFN does not help remdesivir.
In COVID-19 clinical update #84, Dr. Griffin discusses childrens’ antibody response to vaccination, phase 3 results of Novavax vaccine, heterologous vaccination, antithrombotic therapy, EUA for molnupiravir, phase 3 results of AZD7442, serum ferritin levels and outcomes, heparin therapy, and WHO strategy for global vaccination.
In COVID-19 clinical update #83, Daniel Griffin discusses upcoming FDA discussions on vaccines, strategies to prevent transmission at youth camps, outbreaks at summer camps, impact of vaccination on transmission, AZD7442 request for EUA filed, EUA issued for home antigen test, phase 3 data on AZD1222 vaccine, 6 month effectiveness of Pfizer/BioNTech vaccine, estimates of durability of immunity against reinfection, Molnupiravir interim results, optimal time for monoclonal antibody infusion, IVIG plus Infliximab for MIS-C, and effect of vaccination on long COVID.
In COVID-19 clinical update #82, Daniel Griffin reviews vaccines for 5-12 years old, safety of a third vaccine dose, Oklahoma reinfection data, Regencov outcomes, Pfizer protease inhibitor, impact of Tocilizumab, and incidence of long COVID.
In COVID-19 clinical update #81, Daniel Griffin discusses vaccine boosters, vaccination during pregnancy, mRNA vaccine comparison, J&J vaccine booster, EUA expansion for Lilly monoclonals, remdesivir reduces risk of hospitalization, and anticoagulation regimens.
In COVID-19 clinical update #80, Daniel Griffin reviews infections in children, masking, testing to limit transmission, high barrier for monoclonal antibody escape, are boosters needed, use of steroids, grants for long COVID, and how the pandemic unfolds in Africa.
In COVID-19 clinical update #79, Daniel Griffin discusses clinical management guidelines, ER visits and hospitalization among children, infection and vaccine induced seroprevalence in the US, antibodies in Kenyan blood donors, infections after vaccination, anticoagulation for thromboprophylaxis, baracitinib efficacy, long-term symptoms in adults, and sustained symptoms after severe disease.
In COVID-19 clinical update #78, Daniel Griffin covers ivermectin, convalescent plasma, disease in pregnant women, children and COVID, delta outbreak in an elementary school, validation of at-home antigen test, shedding in infected vaccinated people, mRNA vaccine antibody responses compared, AZD7442, fluvoxamine, one year outcomes in hospitalized patients, and post-vaccination disease.
In COVID-19 clinical update #77, Daniel Griffin discusses children becoming increasingly infected, virological characteristics of infections in vaccinated health care workers, transmission dynamics among close contacts, licensing of Pfizer mRNA vaccine, cost of hospitalization of unvaccinated patients, 29 times higher hospitalization rates in unvaccinated patients, boost in neutralizing antibody potency and breadth by third vaccine dose, and use of J&J vaccine as second dose.
In COVID-19 clinical update #76, Daniel Griffin covers association of age and pediatric household transmission, rapid antigen testing in remote communities, shedding of infectious virus in vaccinated individuals, FDA amendment of mRNA vaccine EUA to allow a third dose, new vaccine mandate for NY state, full vaccination suppresses selection of variants, effectiveness of mRNA vaccines in nursing homes, sustained effectiveness of mRNA vaccines against hospitalization, and no benefit from early convalescent serum in high-risk outpatients.